Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04784715 · ClinicalTrials.gov registry record · Phase 3
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
A Phase 3 study of Breast Cancer; HER2-positive; Metastatic, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 1,157
- Enrollment target
- 20
- Study locations
NCT04784715: Active Phase 3 study of Breast Cancer; HER2-positive; Metastatic, sponsored by AstraZeneca.
NCT04784715 is a Phase 3 study of Breast Cancer; HER2-positive; Metastatic that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 1,157 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (50% higher). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04784715, a Phase 3 study of Breast Cancer; HER2-positive; Metastatic, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,157 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study will evaluate the efficacy and safety of trastuzumab deruxtecan (also known as T-DXd, DS-8201a), either alone or in combination with pertuzumab, in treating patients with Human epidermal growth factor receptor 2 (HER2)-positive breast cancer as a first line of treatment in the metastatic setting.
Primary Outcome
Defined as time from date of randomisation until the date of objective radiological disease progression according to Blinded Independent Central Review (BICR) using RECIST 1.1 or death by any cause.
Conditions Studied
Interventions
- DRUG Trastuzumab
- DRUG Placebo
- DRUG Trastuzumab deruxtecan
- DRUG Pertuzumab
- DRUG Taxane
Study Locations (20)
Florida
- Research Site - Miami
- Research Site - Palm Bay
- Research Site - Plantation
California
- Research Site - Glendale
- Research Site - Glendale
New York
- Research Site - New York
- Research Site - Shirley
Arizona
- Research Site - Tucson
Arkansas
- Research Site - Springdale
Colorado
- Research Site - Longmont
Georgia
- Research Site - Atlanta
Kentucky
- Research Site - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,157 participants |
| Start Date | 2021-04-26 |
| Est. Completion | 2029-12-30 |
| Phase | Phase 3 |
What the registry record for NCT04784715 still lists
NCT04784715 is an interventional study that assigns participants to a tested intervention. Its 1,157 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (50% higher).
The record links to 1 condition, with Breast Cancer; HER2-positive; Metastatic appearing as the primary indexed condition, and to 5 interventions - of which Trastuzumab is the first listed.
NCT04784715 names 20 study sites across 16 states, led by Florida, California, New York.
Frequently Asked Questions
What is clinical trial NCT04784715 about?
NCT04784715 is a clinical study titled "Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)". The study will evaluate the efficacy and safety of trastuzumab deruxtecan (also known as T-DXd, DS-8201a), either alone or in combination with pertuzumab, in treating patients with Human epidermal growth factor receptor 2 (HER2)-positive breast cancer as a first line of treatment in the metastatic s...
What is the current status of trial NCT04784715?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,157 participants. The study started on 2021-04-26. Estimated completion is 2029-12-30.
What conditions does trial NCT04784715 study?
This clinical trial studies the following conditions: Breast Cancer; HER2-positive; Metastatic.
What interventions are being tested in trial NCT04784715?
The interventions under investigation include: Trastuzumab (DRUG), Placebo (DRUG), Trastuzumab deruxtecan (DRUG), Pertuzumab (DRUG), Taxane (DRUG).
Who is sponsoring clinical trial NCT04784715?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04784715 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04784715's enrollment target sits among peer trials
1,157 238th of 2000 higher than 1,763 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04577599 · 1,160 participants · NA
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
- NCT07082738 · 1,160 participants · Phase 2
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
- NCT04474301 · 1,152 participants
Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic
- NCT05564026 · 1,151 participants
Molecular Epidemiology of Pediatric Germ Cell Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI